Elevated Risk of Inflammatory Bowel Disease Following Anti-CD20 Therapy in Multiple Sclerosis Patients: Insights from a Swedish Population-Based Cohort
Posted inClinical Updates Gastroenterology Neurology

Elevated Risk of Inflammatory Bowel Disease Following Anti-CD20 Therapy in Multiple Sclerosis Patients: Insights from a Swedish Population-Based Cohort

A Swedish cohort study reveals increased risk of inflammatory bowel disease in relapsing-remitting multiple sclerosis patients treated with rituximab compared to other therapies and the general population, underscoring the need for gastrointestinal vigilance during anti-CD20 treatment.
Efficacy of Rituximab Combined with Pentostatin or Bendamustine in Multiply Relapsed Hairy Cell Leukemia: Insights from a Phase 2 Trial
Posted inHematology-Oncology

Efficacy of Rituximab Combined with Pentostatin or Bendamustine in Multiply Relapsed Hairy Cell Leukemia: Insights from a Phase 2 Trial

This phase 2 trial reveals that both pentostatin-rituximab and bendamustine-rituximab combinations achieve high response rates exceeding rituximab alone in multiply relapsed or refractory hairy cell leukemia, with potential superiority trends favoring pentostatin-rituximab in selected patients.
Posted inClinical Updates Hematology-Oncology news Specialties

Enhanced Progression-Free Survival with Ibrutinib Plus Rituximab in CXCR4-Mutated Waldenström Macroglobulinemia: Insights from a Pooled Analysis

A pooled analysis of prospective studies shows ibrutinib plus rituximab improves progression-free survival in Waldenström macroglobulinemia patients with CXCR4 mutations compared to ibrutinib alone, supporting routine CXCR4 testing and combination treatment strategies.